Cargando…

Synthesis and In Vitro Activity of Novel Melphalan Analogs in Hematological Malignancy Cells

Despite the continuous developments in pharmacology and the high therapeutic effect of new treatment options for patients with hematological malignancies, these diseases remain a major health issue. Our study aimed to synthesize, analyze in silico, and determine the biological properties of new melp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poczta, Anastazja, Krzeczyński, Piotr, Tobiasz, Joanna, Rogalska, Aneta, Gajek, Arkadiusz, Marczak, Agnieszka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836188/ https://www.ncbi.nlm.nih.gov/pubmed/35163680 http://dx.doi.org/10.3390/ijms23031760

Ejemplares similares

Newly Synthesized Melphalan Analogs Induce DNA Damage and Mitotic Catastrophe in Hematological Malignant Cancer Cells
por: Poczta, Anastazja, et al.
Publicado: (2022)

Chemical modification of melphalan as a key to improving treatment of haematological malignancies
por: Gajek, Arkadiusz, et al.
Publicado: (2020)

Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies—Current Research and Clinical Approaches
por: Poczta, Anastazja, et al.
Publicado: (2021)

Antileukemic activity of novel adenosine derivatives
por: Poczta, Anastazja, et al.
Publicado: (2019)

Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
por: Gralewska, Patrycja, et al.
Publicado: (2020)

Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines
por: Gralewska, Patrycja, et al.
Publicado: (2021)

Current Implications of microRNAs in Genome Stability and Stress Responses of Ovarian Cancer
por: Gajek, Arkadiusz, et al.
Publicado: (2021)

Olaparib-Resistant BRCA2(MUT) Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival
por: Biegała, Łukasz, et al.
Publicado: (2023)

Novel oxazolinoanthracyclines as tumor cell growth inhibitors—Contribution of autophagy and apoptosis in solid tumor cells death
por: Rogalska, Aneta, et al.
Publicado: (2018)

The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCA(MUT) and BRCA(WT) Ovarian Cancer Cells
por: Gralewska, Patrycja, et al.
Publicado: (2022)

PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality—An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness
por: Gralewska, Patrycja, et al.
Publicado: (2020)

Two drugs are better than one. A short history of combined therapy of ovarian cancer
por: Bukowska, Barbara, et al.
Publicado: (2014)

Effect of metformin on apoptosis induction in ovarian cancer cells
por: Rogalska, Aneta, et al.
Publicado: (2014)

Hyperglycemia-Associated Dysregulation of O-GlcNAcylation and HIF1A Reduces Anticancer Action of Metformin in Ovarian Cancer Cells (SKOV-3)
por: Rogalska, Aneta, et al.
Publicado: (2018)

Oral Melphalan Therapy in Advanced Malignant Disease
por: Clifford, Peter, et al.
Publicado: (1963)

Abnormal microRNA expression in the course of hematological malignancies
por: Szymczyk, Agnieszka, et al.
Publicado: (2018)

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT
por: Tran, Misha C., et al.
Publicado: (2022)

Melphalan transport into human malignant lymphoid cells differs from the murine equivalent in vitro.
por: Millar, B. C., et al.
Publicado: (1989)

The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.
por: Scott, R. N., et al.
Publicado: (1992)

Synthesis, DFT Calculations, and In Vitro Antioxidant Study on Novel Carba-Analogs of Vitamin E
por: Baj, Aneta, et al.
Publicado: (2019)

Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis
por: Sarosiek, Shayna, et al.
Publicado: (2020)

Synthesis, Biological Activity, ADME and Molecular Docking Studies of Novel Ursolic Acid Derivatives as Potent Anticancer Agents
por: Michalak, Olga, et al.
Publicado: (2023)

Single center experience with total body irradiation and melphalan (TBI-MEL) myeloablative conditioning regimen for allogeneic stem cell transplantation (SCT) in patients with refractory hematologic malignancies
por: Bhatnagar, Bhavana, et al.
Publicado: (2013)

Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan.
por: Moscow, J. A., et al.
Publicado: (1993)

Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies
por: Thompson, J F, et al.
Publicado: (2001)

Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation.
por: Cornbleet, M. A., et al.
Publicado: (1983)

Multinuclear NMR Measurements and DFT Calculations for Capecitabine Tautomeric Form Assignment in a Solution
por: Cmoch, Piotr, et al.
Publicado: (2018)

Hybrid Molecules of Benzylguanidine and the Alkylating Group of Melphalan: Synthesis and Effects on Neuroblastoma Cells
por: Bruchelt, Gernot, et al.
Publicado: (2023)

A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies
por: Solh, Melhem M., et al.
Publicado: (2021)

Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019)

Quassinoid analogs with enhanced efficacy for treatment of hematologic malignancies target the PI3Kγ isoform
por: Pei, Yonggang, et al.
Publicado: (2020)

Factors influencing the chemosensitization of melphalan by misonidazole.
por: Randhawa, V. S., et al.
Publicado: (1985)

Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia
por: Podhorecka, Monika, et al.
Publicado: (2015)

Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan.
por: McElwain, T. J., et al.
Publicado: (1979)

Gastrointestinal Bleeding Secondary to High-Dose Melphalan Pretreatment in Patients with Multiple Myeloma Was Associated with the Mode of Melphalan Administration
por: Ge, Qunfang, et al.
Publicado: (2022)

The effect of hyperthermia in combination with melphalan on drug-sensitive and drug-resistant CHO cells in vitro.
por: Bates, D. A., et al.
Publicado: (1990)

Hierarchy of Factors Affecting the Condition and Development of Sports and Recreation Infrastructure—Impact on the Recreational Activity and Health of the Residents of a City (Poznan Case Study)
por: Kruszyńska, Ewa, et al.
Publicado: (2019)

Difficulties Limiting Access to Sports and Recreational Facilities in the City in the Perceptions of Service Users. Sports and Recreational Infrastructure Management Policy—Poznan Case Study
por: Kruszyńska, Ewa, et al.
Publicado: (2020)

COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic
por: Hus, Iwona, et al.
Publicado: (2023)

CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies
por: Holtan, S G, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_83sm1mebi3o2nuoklmta41tfi9